Sarah James

Q: What is Sarah James's success rate?

Sarah James currently has a success rate of 96.83564859239138.

Q: What is the average return of Sarah James's calls?

Their stock ratings have generated an average return of 8.486977475793289.

Cantor Fitzgerald | Healthcare

Sarah James is an analyst from Cantor Fitzgerald specializing in the Healthcare sector. Ranked #1704 out of 4773 analysts, they have issued 35 stock ratings with a success rate of 96.84% and an average return of 8.49%.

Sarah James has a well-established track record, with 35 ratings issued in the Healthcare sector. They have consistently delivered a success rate of 96.84% and an average return of 8.49%, underscoring their expertise and ability to identify winning opportunities for investors.

#1704

Out of 4773

Total Ratings

+96.84%

Success Rate

+8.49%

Average Return

Recent Ratings Analysis

UHS

Hold

Jul 29, 2026

Target

$194.00

Current

$174.83

Performance

3.97%

Sarah James rated UHS as Neutral on Jul 29, 2026, setting a price target of 194. The Hold stance appears justified, as shares hovered around 174.83 with a 3.97% move.

HUM

Hold

Jul 07, 2026

Target

$300.00

Current

$409.85

Performance

3.86%

On Jul 07, 2026, HUM was given a Neutral rating by Sarah James, with a target price of 300. Market indecision, reflected in sideways trading near 409.85, supported the cautious call.

HCA

Buy

Jul 07, 2026

Target

$525.00

Current

$426.94

Performance

0.91%

HCA received a Overweight rating from Sarah James on Jul 07, 2026, aiming for 525. Price action was muted, as shares hovered around 426.94 despite the bullish outlook.

CNC

Buy

Jul 07, 2026

Target

$75.00

Current

$66.40

Performance

0.42%

On Jul 07, 2026, Sarah James published a Overweight outlook on CNC, with a target of 75. So far, the stock has neither confirmed nor rejected the Buy case, holding within range of 66.4.

ELV

Buy

Jul 07, 2026

Target

$450.00

Current

$418.72

Performance

-0.03%

Sarah James on Jul 07, 2026 assigned ELV a Overweight rating, with a price target of 450. The recommendation remains pending validation as shares consolidate around 418.72.

CVS

Buy

Jul 07, 2026

Target

$110.00

Current

$94.66

Performance

-9.27%

On Jul 07, 2026, Sarah James reaffirmed CVS with a Overweight rating, targeting 110. Shares slid 9.27% despite the recommendation, highlighting downside risks.

MOH

Hold

May 11, 2026

Target

$209.00

Current

$204.23

Performance

10.28%

MOH was rated Neutral by Sarah James on May 11, 2026, with a price objective of 209. Despite caution, upside momentum rewarded risk-takers with gains to 204.23.

ACHC

Hold

May 01, 2026

Target

$30.00

Current

$28.36

Performance

—

On May 01, 2026, Sarah James initiated coverage on ACHC with a Neutral rating and target of 30. The stock’s lack of movement around 28.36 aligned with a cautious approach.

CI

Buy

May 01, 2026

Target

$340.00

Current

$280.76

Performance

—

Sarah James issued a Overweight recommendation for CI on May 01, 2026, price target set at 340. The target of 340 remains in play, though confirmation will depend on future moves.

TBRG

Hold

Apr 24, 2026

Target

$26.25

Current

$26.24

Performance

—

On Apr 24, 2026, TBRG was evaluated by Sarah James, who gave a Neutral rating and target of 26.25. Hold sentiment was validated by subdued trading with no breakout beyond 26.24.

NYXH

Buy

Mar 23, 2026

Target

$11.00

Current

$1.54

Performance

-51.27%

Sarah James rated NYXH as Overweight on Mar 23, 2026, setting a price target of 11. The stock has underperformed, dropping 51.27% despite the bullish target of 11.

DCGO

Buy

Mar 17, 2026

Target

$3.00

Current

$0.35

Performance

-54.69%

On Mar 17, 2026, DCGO was given a Overweight rating by Sarah James, with a target price of 3. Despite the Buy call, shares fell from 0.3523 to 0.3523, challenging the optimistic stance.

HCAT

Hold

Mar 13, 2026

Target

$4.00

Current

$1.70

Performance

28.79%

HCAT received a Neutral rating from Sarah James on Mar 13, 2026, aiming for 4. Investors saw gains of 28.79% that the cautious stance didn’t fully capture.

MDXG

Buy

Feb 17, 2026

Target

$12.00

Current

$4.57

Performance

-11.43%

On Feb 17, 2026, Sarah James published a Overweight outlook on MDXG, with a target of 12. Market action contradicted the Buy thesis, as shares slipped to 4.57.

THC

Buy

Oct 29, 2025

Target

$245.00

Current

$263.69

Performance

26.08%

Sarah James on Oct 29, 2025 assigned THC a Overweight rating, with a price target of 245. The Buy call aligned well with market performance, producing a gain of 26.08%.

SGRY

Buy

Oct 07, 2025

Target

$36.00

Current

$14.38

Performance

-29.48%

On Oct 07, 2025, Sarah James reaffirmed SGRY with a Overweight rating, targeting 36. Shares slid 29.48% despite the recommendation, highlighting downside risks.

UNH

Buy

Aug 26, 2025

Target

$440.00

Current

$379.09

Performance

26.18%

UNH was rated Overweight by Sarah James on Aug 26, 2025, with a price objective of 440. A bullish response from the market helped close the gap of 60.91 to the target.

PGNY

Buy

Aug 08, 2025

Target

$28.00

Current

$27.35

Performance

19.69%

On Aug 08, 2025, Sarah James initiated coverage on PGNY with a Overweight rating and target of 28. The stock’s climb of 19.69% since the call highlights the foresight in the rating.

LFMD

Buy

Mar 11, 2025

Target

$15.00

Current

$3.05

Performance

-45.34%

Sarah James issued a Overweight recommendation for LFMD on Mar 11, 2025, price target set at 15. The market hasn’t rewarded the bullish outlook, exposing uncertainty in the call.

RCM

Hold

Oct 04, 2024

Target

$14.30

Current

$14.31

Performance

0.85%

On Oct 04, 2024, RCM was evaluated by Sarah James, who gave a Neutral rating and target of 14.3. Hold sentiment was validated by subdued trading with no breakout beyond 14.31.

TDOC

Buy

Aug 20, 2024

Target

$10.00

Current

$6.16

Performance

-14.44%

Sarah James rated TDOC as Overweight on Aug 20, 2024, setting a price target of 10. The stock has underperformed, dropping 14.44% despite the bullish target of 10.

AMED

Hold

Jul 25, 2024

Target

$101.00

Current

$100.99

Performance

3.31%

On Jul 25, 2024, AMED was given a Neutral rating by Sarah James, with a target price of 101. Market indecision, reflected in sideways trading near 100.99, supported the cautious call.

Frequency Asked Questions

Who is Sarah James?

Sarah James is an analyst from Cantor Fitzgerald specializing in the Healthcare sector.

What is Sarah James's success rate?

Sarah James currently has a success rate of +96.84%.

How many ratings has Sarah James issued?

Sarah James has issued 35 stock ratings so far.

What is the average return of Sarah James's calls?

Their stock ratings have generated an average return of +8.49%.

What is Sarah James's ranking?

Sarah James is ranked #1704 out of 4773 analysts.

What types of ratings does Sarah James give?

Their ratings include Buy, Hold, and Sell recommendations, depending on the stock’s outlook.

How can I follow Sarah James?

You can follow Sarah James by clicking the "Follow Analyst" button on this page to receive updates on their stock calls.

What is the most recent rating by Sarah James?

Their latest rating was a Hold on UHS issued on 2026-07-29.